US Patent

US12453721 — Topical roflumilast aerosol foams

Formulation · Assigned to Arcutis Biotherapeutics Inc · Expires 2042-08-19 · 16y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a topical roflumilast aerosol foam composition for delivery, comprising roflumilast, a specific emulsifier blend, and a propane/isobutane/butane propellant.

USPTO Abstract

The present invention is directed to an aerosol foam composition comprising roflumilast, an emulsifier blend containing cetearyl alcohol, dicetyl phosphate, and ceteareth-10 phosphate and a hydrocarbon propellant. The aerosol foam composition is preferably an oil in water emulsion. The propellant is a mixture of liquefied hydrocarbon gases preferably a propane/isobutane/butane blend. The hydrocarbon propellant results in an aerosol foam which is stable, has consistent physical properties, excellent aesthetics, and no discernable degradation after long term or accelerated storage conditions.

Drugs covered by this patent

Patent Metadata

Patent number
US12453721
Jurisdiction
US
Classification
Formulation
Expires
2042-08-19
Drug substance claim
No
Drug product claim
Yes
Assignee
Arcutis Biotherapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.